IJCRR - 7(24), December, 2015
IMMUNOTHERAPEUTIC TREATMENT OF HIV-1: REVIEW OF SAFETY AND EFFICACY
Author: Kariuki, SM, Musyoki, SK and Kemoi, EK
Background: For over two decades, the treatment of HIV-1 patients has relied on antiretroviral (ART). These drugs have had a great deal of achievement in not only controlling the viral load but also partly reconstituting the immune system in HIV-1 infected persons. However, the misfortune is that ART is a lifelong treatment because it cannot achieve complete eradication of HIV-1 virus, yet with its side effects like many other drugs. Scientists have hence introduced immunotherapy in an effort toward complete eradication of HIV-1 in HIV/AIDS patients.
Objective: The aim of this paper was to determine the effectiveness and safety of the various immunotherapy formats used in the treatment of HIV-1 infection.
Method: We reviewed a number of peer-reviewed published articles to determine the effectiveness and safety of the different immunotherapy formats tested in randomized clinical trials and animal model experiments.
Results: Majority of immunotherapy regimens used in combination with ART to treat HIV-1 positive human or animals were found to be effective in boosting the cell-mediated immune responses in HIV-1 infection but achieved insignificant results in controlling the viral load in these experiments. Most of the immunotherapy formats were also well tolerated recording minimal to no adverse effects on HIV-1 patients.
Conclusion: Most immunotherapy agents are relatively effective and safe when used in combination with ART in modulating immune response to HIV-1. These immunotherapy agents do not significantly reduce the viral load and hence cannot eliminate HIV-1.
Keywords: Immunotherapy, HIV-1, ART, HIV/AIDS, Effectiveness, Efficacy, Safety
Kariuki, SM, Musyoki, SK and Kemoi, EK. IMMUNOTHERAPEUTIC TREATMENT OF HIV-1: REVIEW OF SAFETY AND EFFICACY International Journal of Current Research and Review. 7(24), December, 24-29
1. Haes W De, Pollard C, Vanham G, Rejman J. “ Wrapped Up ” Vaccines in the Context of HIV-1 Immunotherapy. 2012;41.
2. Poonia B. Infectious Diseases and Therapy Immunotherapy in HIV Infection. 2013;1(1):1–5.
3. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS pathogens [Internet]. 2014 Jan [cited 2014 Nov 2];10(1):e1003872. Available from: http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3887103 andtool=pmcentrezandrendertype=abstract
4. Vanham G, Van Gulck E. Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1 Retrovirology [Internet]. Retrovirology; 2012 Jan [cited 2014 Nov 16];9(1):72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3472319andtool=pmcent rezandrendertype=abstract
5. Luban J. Innate immune sensing of HIV-1 by dendritic cells. Cell host and microbe [Internet]. Elsevier Inc.; 2012 Oct 18 [cited 2014 Nov 16];12(4):408–18. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3619430andtool=pm centrezandrendertype=abstract
6. Chun T-W, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS (London, England) [Internet]. 2012 Jun 19 [cited 2014 Nov 5];26(10):1261–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22472858
7. Pett SL, Kelleher AD. Cytokine therapies in HIV-1 infection: Present and future [Internet]. Expert Review of Anti-Infective Therapy. 2003. p. 83–96. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-2942557197andpartnerID=tZOtx3y1
8. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nature Reviews Immunology [Internet]. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2013 Aug 23 [cited 2015 Sep 28];13(9):693–701. Available from: http://dx.doi.org/10.1038/nri3516
9. Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases [Internet]. Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. Elsevier; 2015 [cited 2015 Sep 23]. 39-49 p. Available from: http://www. sciencedirect.com/science/article/pii/B9780128013175000037
10. Smith K a, Andjelic S, Popmihajlov Z, Kelly-Rossini L, Sass A, Lesser M, et al. Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial. PLoS clinical trials [Internet]. 2007 Jan [cited 2014 Nov 16];2(1):e5. Available from: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=1783674andtool=pmcentrezandrender type=abstract
11. Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 coinhibitory pathway in HIV infection and potential therapeutic options. 2015;1–17.
12. Roff SR, Noon-Song EN, Yamamoto JK. The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Frontiers in immunology [Internet]. 2014 Jan 13 [cited 2014 Nov 10];4(January):498. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3888948andtool=pmcent rezandrendertype=abstract
13. Jarvis JN, Meintjes G, Rebe K, Ntombomzi G, Bicanic T, Williams A, et al. Europe PMC Funders Group Adjunctive Interferon- γ Immunotherapy for the Treatment of HIV- associated Cryptococcal Meningitis : A Randomized Controlled. 2013;26(9):1105–13.
14. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, Jha AR, et al. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. Journal of clinical immunology [Internet]. 2010;30(5):681–92. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0- 77957571862andpartnerID=tZOtx3y1
15. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361(16):1548–59.
16. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, Jha AR, et al. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. Journal of clinical immunology [Internet]. 2010 Sep [cited 2014 Nov 16];30(5):681–92. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=2935971andtool= pmcentrezandrendertype=abstract
17. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler S a. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clinical and vaccine immunology : CVI [Internet]. 2008 Feb [cited 2014 Nov 16];15(2):284–92. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgiartid=2238066andtool= pmcentrezandrendertype=abstract
18. Huang X-L, Fan Z, Borowski L, Rinaldo CR. Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. Journal of leukocyte biology [Internet]. 2008 Jun [cited 2014 Nov 16];83(6):1530–40. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/18364435
19. Chen Y, Wang S, Lu S. DNA Immunization for HIV Vaccine Development. Vaccines [Internet]. 2014 Feb 25 [cited 2014 Nov 16];2(1):138–59. Available from: http://www.mdpi.com/2076- 393X/2/1/138/
20. Palma P, Gudmundsdotter L, Finocchi A, Eriksson L, Mora N, Santilli V, et al. Immunotherapy with an HIV-DNA Vaccine in Children and Adults. Vaccines [Internet]. 2014 Jul 17 [cited 2014 Nov 16];2(3):563–80. Available from: http://www.mdpi. com/2076-393X/2/3/563/
21. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006;194(12):1661–71.
22. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nature medicine [Internet]. 2003 Jul;9(7):861–6. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/12835706
23. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(41):16538–43. Available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3799352andtool= pmcentrezandrendertype=abstract